Orthopaedic joint replacement is generally considered 'clean' surgery characterized by a low incidence of infection. In recent years the use of a clean theatre environment, high local concentrations of antibiotic in the cement and systemic antibiotic prophylaxis have been recognized as important measures to reduce infection rates significantly, and this has been supported by clinical trials. Staphylococcus aureus and Staphylococcus epidermidis cause at least half of all orthopaedic surgical infections. Gram-negative bacilli are involved to a much lesser extent (10-30%). First-and second-generation cephalosporins are currently considered by most authors as standard prophylaxis in elective orthopaedic surgery. In the light of the increasing incidence of methicillin resistance in coagulase-positive and -negative staphylococci, it is becoming more important for antibiotics to act efficiently against such organisms if they are to be of value in prophylaxis in orthopaedic surgery. A combined, single-dose of vancomycin/gentamicin has been used successfully in an open, controlled study in patients undergoing total joint arthroplasty but, given the disadvantages associated with the use of vancomycin, teicoplanin may be an alternative choice in such procedures. This review analyses four comparative trials of the efficacy and safety of teicoplanin, two with cefamandole, one with cefuroxime and one with cephazolin, as prophylaxis in orthopaedic total joint replacement surgery.
Introduction
The replacement of diseased or damaged joints with prostheses is a major accomplishment of modern orthopaedic surgery. Currently, infection represents the most feared and, perhaps, the most serious complication of prosthetic joint surgery. 1 Although it occurs in only a small proportion of patients, the large number of such procedures performed annually makes this problem significant, and when infection does occur the outcome can be devastating, resulting in total loss of joint function, amputation and, occasionally, death. 2 Consequently, antimicrobial prophylaxis, usually reserved for contaminated orthopaedic surgery, is today also recommended for any clean procedure involving implantation of orthopaedic prostheses to prevent the severe clinical and economic consequences of sepsis. 3, 4 Infection in an orthopaedic prosthesis has been arbitrarily classified as 'early' if it occurs within 3 months of placement. Infection occurring within this time-frame is generally considered to be caused by the ingress of bacteria during the peri-operative period. Infection after 3 months is classified as 'late', and usually occurs within the first year. 5 Such infections tend to be low grade, to develop slowly and to be difficult to diagnose, and can be the consequence of blood-borne infection, though the cause may also be from the few organisms seeded at the time of operation. [6] [7] [8] [9] [10] [11] [12] In most orthopaedic surgical procedures the bacterial contamination and eventual infection are usually from an exogenous source; the organisms most commonly causing deep wound infection are Staphylococcus aureus and coagulase-negative staphylococci (particularly Staphylococcus epidermidis). Other organisms isolated from infected prosthetic joints include aerobic and anaerobic streptococci and a variety of Gram-negative bacilli. 1, 2, 11, [13] [14] [15] [16] Factors increasing the incidence of infection include the duration of the operation, the length of preoperative hospitalization, rheumatoid arthritis, previous surgery performed on the joint, and the anatomic site. The rate of infection in clean orthopaedic surgery varies according to the procedure performed. Reported rates of deep infection are 1.3-11% in total hip replacement, and 0.7-9% in knee arthroplasty. 17 The infection risk in elective orthopaedic surgery involving prosthetic implants is, on average, significantly greater in total knee replacement than in total hip replacement. 11 Avoiding prosthetic contamination upon insertion is mandatory, and the use of laminar flow has been shown to be an important preventive measure. 18 There is now conclusive evidence that hypersterile operating conditions decrease the number of air-borne organisms, and can significantly reduce the infection rate compared with surgery performed in conventional operating theatres. 7, [18] [19] [20] Additional factors that have led to a decrease in the frequency of infection following total joint arthroplasty in recent years include improved surgical technique and the use of ultraviolet light, antibiotic-impregnated methylmethacrylate and systemic prophylactic antibiotics. [21] [22] [23] [24] [25] Of the measures most commonly used to reduce the risk of infection in orthopaedic implants (i.e. ultraclean air in vertical unidirectional flow, and antibiotics used systemically or in cement), and those taken to avoid infection common to all surgery, the most powerful procedure is the use of antibiotics. 26 These authors found that systemic prophylaxis reduced the infection rate of 3.4% that is found in conventionally ventilated theatres by four-fold, and that ultraclean air systems reduced it by another half. Protective clothing, such as body-exhaust suits, helped further reduce infection by 0.5%.
Principles of antimicrobial prophylaxis in orthopaedic surgery
Today, arguments centre around the timing of dosage, duration, route of administration and choice of prophylactic antibiotics rather than the need for their use; failure to use antibiotics has been estimated to result in a sevenfold increase in the rate of infection. 7 Many studies have now established that timing is critical to the efficacy of surgical antimicrobial chemoprophylaxis; antibiotic treatment must be given before surgery in order to ensure high levels in the tissues at the time of contamination. 16, 27, 28 However, to achieve optimum effects, the antibiotic should not be administered too early in the preoperative period. 3, 7, 17 As in other branches of surgery, providing the kinetics and timing are correct, there is emerging evidence in orthopaedic surgery that single-dose prophylaxis is adequate and that additional peri-operative antibiotics should not be necessary. 16, 18, [28] [29] [30] [31] [32] [33] Optimum antiseptic efficacy is achieved when an antimicrobial agent is administered intravenously to provide at equal dose the highest blood concentrations, and thus the maximum and most rapid penetration into the extravascular compartment. 34 The interval between intravenous dosing and the start of surgery should be reduced to 20-30 min to allow saturation of bone, joint soft tissue or haematoma. 18 The half-life of the drug determines the number of perioperative doses needed to ensure maximum antiseptic efficacy using the minimum amount necessary to provide full antimicrobial cover. A single, pre-operative dose can provide optimum chemoprophylaxis when the half-life is longer than the surgery time. 7, 16, 18, [35] [36] [37] [38] Tissue penetration of antibiotics active against Gram-positive bacteria
In orthopaedic surgery the chemoprophylactic agent must reach the bone and surrounding soft tissues at adequate concentrations during the operation (i.e. at the time of potential bacterial contamination). Although data from clinical studies are scarce, adequate concentrations at the time of surgery should be well in excess of the mean MIC for the bacteria most often causing postoperative infections of the wound, if the outcome is potentially lifethreatening. 18, 32, 37, 39 Antibiotics that have been reported to penetrate bone well are clindamycin, gentamicin, flucloxacillin, cephazolin, cefamandole, cefuroxime, cefoxitin, ceftriaxone, ceftazidime, rifampicin, ofloxacin, pefloxacin, vancomycin and teicoplanin. 35, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] Teicoplanin is widely distributed in a variety of tissues and fluids, except for cerebrospinal fluid. Concentrations in bone are 65% of those in serum, and the peak is reached within 0.5-6 h after rapid, intravenous administration of teicoplanin 400 mg. The results at the end of surgery suggest that levels in excess of the MIC 90 of Gram-positive cocci, S. aureus and S. epidermidis as well as enterococci, will be obtained in serum and bone for 3 h. 58 On the basis of the favourable pharmacokinetic characteristics described, as well as the antimicrobial properties (i.e. activity against Gram-positive bacteria) and the low toxicity, the first-and second-generation cephalosporins (such as cephazolin, cefamandole and cefuroxime) are considered the prophylactic antibiotics of choice in total hip or knee replacement. 7, 13, 20, 28, [59] [60] [61] [62] In particular, cephazolin has been the most often used and recommended agent in this setting. 20, [59] [60] [61] [62] [63] After an intravenous bolus dose of cephazolin 2 g, bone concentrations are well above the MBC for methicillin-susceptible staphylococci. 62 However, there is a real need for alternative antibiotics, such as the fluoroquinolones and glycopeptides (vancomycin and teicoplanin). The pharmacokinetic data and activity of these agents against Gram-positive bacteria, including -lactamase-producing and methicillin-Review resistant staphylococci, qualify them as effective agents to provide valid peri-operative prophylactic cover. 46, [64] [65] [66] [67] [68] [69] [70] 
Choice of antibiotic
As most infections in joint prostheses are caused by staphylococci, antibiotic prophylaxis is generally directed against Gram-positive bacteria. Cephalosporins, semisynthetic penicillins, fluoroquinolones and glycopeptides have the desired spectrum of activity, safety and tissue penetration. 13, 35, 39, 62, 64, 65, 67, 71 The most widely used antibiotics in total joint replacement procedures are the firstand second-generation cephalosporins by virtue of their excellent activity against the pathogens commonly involved in joint prosthesis infections, and their favourable pharmacokinetics and safety. 13, 62, 63, 71 The preferred agents are cephazolin and cefamandole. Multiple doses (pre-and post-intervention) of cephazolin are today considered by most authors as standard prophylaxis during clean surgical procedures, including elective orthopaedic surgery, if methicillin-resistant staphylococci have not been isolated in the nosocomial environment. 10, 20, 22, 31, 59, 61, [72] [73] [74] [75] [76] [77] Pefloxacin has been the only fluoroquinolone to be studied as a prophylactic agent in hip or knee replacement surgery. [78] [79] [80] [81] [82] It has been shown to be as effective and welltolerated as comparative cephalosporins (cefamandole, cephazolin, ceftazidime and ceftriaxone). [79] [80] [81] [82] The inhibitory activity of these drugs is, however, somewhat lower against staphylococci than Gram-negative bacteria, and staphylococcal MICs are generally close to the breakpoint of susceptibility. There is also evidence of increasing staphylococcal resistance, particularly in methicillinresistant strains, during treatment with fluoroquinolones. This has been associated with the extensive use of these antibiotics in the hospital setting. [83] [84] [85] [86] The glycopeptide antibiotics, teicoplanin and vancomycin, represent valid alternative for prevention of infection following orthopaedic surgery. 13, 64, 71 Considering the growing incidence of methicillin-resistant coagulasepositive and -negative staphylococci in nosocomial infections, it is becoming more important for antibiotics to act efficiently against these bacteria if they are to be of value for prophylaxis in orthopaedic surgery. 84, 87, 88 A combined, single-dose vancomycin/gentamicin regimen has been used successfully in an open, controlled study in patients undergoing unilateral or bilateral total joint arthroplasty. 89 Recommendations for the use of vancomycin alone as an alternative peri-operative antimicrobial prophylactic agent in orthopaedic prosthetic surgical procedures have been made. 31, 32, 71, [90] [91] [92] However, vancomycin is more difficult to administer (by long-term intravenous infusion only) and has a shorter half-life than teicoplanin. Results of a recent meta-analysis of 11 randomized, clinical trials conducted in patients with either febrile neutropenia or severe Gram-positive infections, including those with methicillin-resistant S. aureus, suggest that vancomycin is as effective as teicoplanin, but is tolerated significantly less well. 93 Perioperative antibiotic prophylaxis with vancomycin is also characterized by anaphylactoid reactions, such as significant hypotension and the 'red man' syndrome. 92, 94, 95 Teicoplanin may be an optimal choice in this setting as it is active against staphylococci, including methicillin-resistant strains. 64, 96, 97 Teicoplanin has a long half-life, low toxicity and good tissue penetration, 64, 98 which allows it to achieve therapeutically valid concentrations in bone and the surrounding soft tissue (references 51,57,65, and Garaud, J. J., Cavenaghi, L. & Girat, T., data on file, Merrell Dow Research Institute). The recent recognition of increasing resistance to glycopeptides among Gram-positive bacteria, however, [99] [100] [101] has caused concern that glycopeptideresistant strains of S. aureus and coagulase-negative staphylococci will assume clinical importance. 102 This makes it prudent to limit the use of these agents for shortterm antimicrobial prophylaxis in orthopaedic surgical procedures in institutions in which methicillin-resistant S. aureus or S. epidermidis are important wound pathogens, 103 or in patients allergic to -lactam antibiotics.
Clinical trials with teicoplanin

Studies
Four comparative trials of the efficacy and safety of teicoplanin as antimicrobial prophylaxis in orthopaedic surgery have been performed. Two were carried out in the UK, and compared teicoplanin with cefuroxime, 104 or cefamandole, 72 while the other two were conducted in Italy and compared teicoplanin with cefamandole or cephazolin. [73] [74] 77 The first pivotal trial was an unblinded, randomized study comparing a single dose of teicoplanin against four cefamandole doses over a 24 h period in patients undergoing prosthetic joint surgery (hip or knee arthroplasty) at the Musgrave Park Hospital, Belfast. 72 A total of 899 patients was entered into the study; of these 19 did not receive study medication and were not considered further. Patients were assessed for evaluability on an 'intent-totreat' (n 880) or 'per protocol' (n 765) basis (Table I) . Of the 115 protocol violations, most resulted from inappropriate randomization. Patients were randomly allocated to two groups to receive either teicoplanin 400 mg iv at the induction of anaesthesia, or cefamandole 2 g iv at induction and 1 g every 6 h for 18 h after the operation. Most patients received gentamicin bone cement during their operations. The remainder received a cementless artificial joint. A primary failure was defined as a wound infection with proven bacteriology. Infections at all other sites were reported as secondary failures or complications. Efficacy was determined on the basis of post-operative wound infection assessed at 8-10 days, 1 month and 6-18 months post-operation.
The second pivotal clinical study was a multicentre, comparative, randomized study of a single dose of teicoplanin compared with five doses of cephazolin in patients undergoing hip or knee replacement in 12 centres in Italy. 69, [73] [74] Patients were randomized to receive either teicoplanin 400 mg iv at the induction of anaesthesia, or five doses of cephazolin 2 g at induction plus four 1 g iv doses spread over 24 h post-operatively. A total of 860 patients was enrolled, and 14 were excluded from data analysis due to pre-operative protocol violations (i.e. positive pre-operative urine culture or antibiotic therapy in the week before surgery). Twenty patients were not evaluable for efficacy as an unjustified antibiotic treatment had been administered post-operatively. Thus, 846 and 826 patients were evaluated for safety and efficacy, respectively (Table I) . A primary failure was defined as a wound infection with or without proven bacteriology. Infections at other sites were reported as secondary failures or complications. Early assessments were performed in the post-operative stay and at 3 months, while a long-term follow-up was performed at 12 months.
Two further clinical studies were conducted in the UK and Italy, and compared teicoplanin 400 mg iv at the induction of anaesthesia with three doses of cefuroxime and two doses of cefamandole, respectively. 77, 104 Cefuroxime was administered as three 750 mg iv doses, one at pre-medication, one at induction of anaesthesia and one 8 h post-operatively. Cefamandole 2 g iv was given before surgery and 1 g was given after surgery. In all, 146 patients were enrolled in the UK study (72 receiving teicoplanin and 74 receiving cefuroxime). The Italian trial recruited 520 patients, of whom 250 receiving teicoplanin and 246 receiving cefamandole were evaluable for efficacy (Table I) . In both studies, efficacy was assessed by wound scores and wound infections during the post-operative hospital stay.
Exclusion criteria common to all four studies were age (14 or 18 years), known allergy to study drugs, active infection or significant bacteriuria at time of operation, antibiotic therapy in the 2 weeks preceding operation, pregnancy or lactation, and renal impairment.
The study methods used in the four trials considered here (including the selected patient populations and prophylactic regimens) did not differ substantially. The overall analysis of treatment effects was thus valid. The statistical methods appropriate for analysing data from retrospective randomized studies have been described in detail elsewhere. 105, 106 All analyses were based on individual data. Treatment effects on failure and adverse event rates were estimated initially within each trial, and then overall. These data were analysed using the Mantel-Haenszel 2 statistic. 105 The results were examined in terms of odds ratios and their 95% confidence intervals (CIs). For a first approximation, an odds ratio can be thought of as the relative risk of an event occurring in the teicoplanin group compared with the risk of its occurrence in the cephalosporin group. An odds ratio between 0 and 1 indicates a benefit of treatment with teicoplanin compared with cephalosporins, while an odds ratio of 1 indicates a benefit of cephalosporins over teicoplanin. The benefit is statistically significant when the 95% CI of the odds ratio does not include unity. Heterogeneity between trials was evaluated by the 2 test. Calculations were performed using appropriate statistical software (Statistica, Release 5.0, 1997 from Stata Corporation, College Station, TX, USA). Odds ratios and statistical results are reported in detail for primary failure data (Table II) . For all other efficacy and safety data comparisons, only statistically significant differences or trends are indicated.
Patient population
The four studies were comparable with regard to major patient characteristics and risk factors. No clinically relevant differences were seen among the studies or between treatment groups for sex distribution, age, body weight or duration of surgery.
Efficacy
Wound infection. Table II summarizes the efficacy results, expressed as wound infections, for the four studies of orthopaedic prophylaxis. Early wound infection rates (i.e. those occurring within 3 months of the operation) were comparable for all the studies. In the study by Wall et al., 104 bacteriology was reported for all patients with suspected wound infection. However, the number of wound infections was not evaluated.
In the study by Mollan et al., 72 in the 'intent-to-treat' analysis, nine early wound infections (1%) occurred, three (0.8%) in the teicoplanin group and six (1.2%) in the cefamandole group. The difference between study treatments was not significant. Similar results were obtained analysing data 'per protocol'. Details are given in Table II . In the study by Periti et al., 69, [73] [74] 19 early wound infections were recorded (2.3%), with no difference between the two treatment groups; nine (2.2%) in the teicoplanin group and ten (2.4%) in the cephazolin group.
In the Suter et al. 77 study the only infectious complications were seen in the cefamandole group (Table II) . According to these authors, the difference between the groups was not statistically significant (P 0.059 by using Fisher's exact test). Analysis of these data by the MantelHaenszel procedure, however, generated a P value of 0.043, suggesting a significant difference at this significance level.
The overall wound infection rate seen in the study by Wall et al. (6.8%) was significantly higher than those obtained in the other three studies (0.8% in the Suter study, 1.0% in the Mollan study and 2.3% in the Periti study). 69, [72] [73] [74] 77, 104 There was no significant difference between the regimens in the development of wound infection (5.5% for teicoplanin and 8.1% for the comparator cephalosporin cited, i.e. cefuroxime).
Data on long-term assessment at 6-18 or 24 months are available for the pivotal studies. In the Mollan study, of the 880 patients enrolled, 6-18-month follow-up reports are available for 842 patients (95.7%, 'intent-to-treat' analysis). 72 Three late wound infections occurred; one (0.3%) in the teicoplanin group and two (0.4%) in the cefamandole group. In the Periti study, clinical data from 683 patients (79.4%) were available at the 12-month follow-up. 69, [73] [74] One primary failure was seen in each of the teicoplanin (0.3%) and cephazolin (0.3%) groups. No late wound (24-month follow-up) infectious complications were seen in either treatment group in the Suter study (all 496 patients evaluable). 77 No long-term assessment data are available for the study by Wall et al. 104 The pathogens most commonly encountered were Gram-positive organisms (77.8%, Table III) . S. aureus, S. epidermidis and other coagulase-negative staphylococci accounted for 53.3% of total isolates. In the study by Mollan et al., 72 66.7% of pathogens isolated from wound infections were S. aureus and coagulase-negative staphylococci. In the Periti study, 69, 73, 74 15 of 21 wound infections were bacteriologically proven, of which eight (53.3%) were caused by staphylococci. For the supporting studies by Suter et al. 77 and Wall et al., 104 staphylococci accounted for 16.7% and 58.3%, respectively, of pathogens isolated from positive wound cultures. Table IV gives a breakdown of overall wound infection rates by the type of joint replacement for the major orthopaedic surgery studies. It has been reported that knee replacement surgery involves a significantly higher risk of infection than hip replacement. 11 The Mollan study supports this observation since the overall wound infection rates on an intent-to-treat basis were 3.2% and 0.8% for knee and hip replacement, respectively. 72 The results of Periti's study show an inverse trend, even though the higher wound infection rate seen in hip compared with knee replacement surgery (1.8% and 0.7%, respectively) was not significant. 69, [73] [74] No statistically significant differences were seen between treatment arms in either of these studies, according to type of joint replacement.
Secondary infections. The incidence of secondary infections (i.e. infections at sites remote from the wound) shows agreement between treatment in the three studies in which this parameter has been evaluated (Table V) . 72, 74, 77 Although the overall incidence of wound infection was the same in the Mollan study, the incidence of urinary tract infection (UTI) was significantly higher in the teicoplanin group, with almost twice as many Gram-negative infections occurring, while the number of lower Review respiratory tract infections (LRTIs) was significantly higher in the cefamandole arm. 72 In the Periti and Suter studies, Gram-negative organisms were the predominant causative agents of UTI and LRTI in both treatment groups. 74, 77 However, it is recognized that antimicrobial prophylaxis is only beneficial in the prevention of infections at the surgical site. It has no role in the prevention of secondary post-operative infections, such as LRTI and UTI. 107 
Safety
Tables VI and VII summarize the adverse events seen in the four studies as total adverse events and adverse events related to the study drug, as judged by the investigator. The incidence of adverse events was similar for the two treatment groups within each study, and was generally low. In the study by Periti et al., 74 a higher incidence of adverse events was observed in the cephazolin group (2.1% vs 0.7% in the teicoplanin group), though this difference did not reach statistical significance. Also, of the nine patients with adverse events in the cephazolin group, only two had events related to the study drug. Of 1140 patients receiving teicoplanin who were evaluable for safety, the overall incidence of adverse events was 5.1% (58 patients) of whom 1.0% (11 patients) had events attributed to the study drug. In comparison, 1252 patients received cephalosporins, of whom 6.5% (82 patients) experienced adverse events, with 1.0% (12 patients) being related to the study drug. Analyses of laboratory data in the studies by Mollan et al. 72 and Periti et al. 74 showed marked changes from baseline for haematological and biochemical parameters. 69, [72] [73] [74] However, these were comparable between the treatment groups and considered to be related to the effects of operation. (2) deep vein thrombosis (4) pyrexia (1) intestinal obstruction (1) suspected pulmonary embolism (1) swollen ankle (1) It can be concluded, on the basis of results of the four randomized studies, that single-dose teicoplanin has efficacy and safety equivalent to multiple-dose cephem antibiotics (cephazolin, cefamandole or cefuroxime) in the prevention of post-prosthetic joint infection. The number of patients required to show a statistical difference is large.
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For example, to demonstrate a reduction in infection rate from 2% to 1% with a power of 90% at the 95% CI, a study would need over 3000 patients per group. The practicalities of producing a trial in this area with such large patient numbers makes demonstrating such a difference unlikely. The studies presented here included 2406 patients, of whom 2233 were evaluable for efficacy on a 'per protocol' and 2348 on an 'intent-to-treat' basis. The two major studies together represent 1740 patients, of whom 1591 were evaluable. The infection rates seen in the two pivotal studies were 0.5-1.5% for teicoplanin and 0.4-1.7% for the comparator cephalosporin at the early assessment within 3 months of operation. At the long-term assessments, conducted 6-18 months post-operation, wound infection rates were 0.3% in both studies for teicoplanin and 0.3-0.4% for the comparator cephalosporins. These rates are comparable to published studies of antimicrobial prophylaxis in orthopaedic surgery, where rates of 0.5-4% have been reported following prophylaxis with cephalosporins, such as cephazolin, cefamandole and cephaloridine. Some of these studies used up to 5 day dosing regimens of the prophylactic antibiotic. No significant difference in the incidence of adverse drug events between teicoplanin and the comparator cephalosporins was observed.
The microbiological results of the four studies confirm that Gram-positive bacteria are the primary pathogens responsible for wound infection in prosthetic joint surgery, accounting for approximately 78% of isolates. S. aureus and coagulase-negative staphylococci were predominant (about 53%). The results from these studies demonstrate that a single, peri-operative dose of teicoplanin can represent a valid alternative to multiple administration of antimicrobial drugs with a short half-life in preventing infection following total hip and total knee replacement. Teicoplanin has a good spectrum of antimicrobial activity against primary pathogens responsible for wound infection in orthopaedic surgery. In particular, it is highly active against staphylococci, both methicillin-sensitive and methicillin-resistant strains, which are the most common pathogens in prosthetic orthopaedic surgery. Teicoplanin also has excellent tissue penetration and low toxicity. Its elimination half-life is exceptionally long, outlasting the mean operating times in orthopaedic implant surgery, making it suitable for peri-operative prophylaxis.
Teicoplanin as a single 400 mg dose by rapid intravenous route at induction of anaesthesia may represent a reasonable choice for use in antimicrobial prophylaxis in all orthopaedic surgical procedure associated with a high risk of infection due to Gram-positive bacteria, particularly methicillin-resistant strains of S. aureus and S. epidermidis.
